Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel® macrocarriers

Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel® macrocarriers

The COVID-19 pandemic has led to high global demand for vaccines to safeguard public health. To that end, our institute has developed a recombinant viral vector vaccine utilizing a modified vesicular stomatitis virus (VSV) construct, wherein the G protein of VSV is replaced with the spike protein of...

Full description

Bibliographic Details
Main Authors: Noam Cohen, Irit Simon, Ophir Hazan, Arnon Tal, Hanan Tzadok, Lilach Levin, Meni Girshengorn, Lilach Cherry Mimran, Niva Natan, Tzadok Baruhi, Alon Ben David, Osnat Rosen, Shlomo Shmaya, Sarah Borni, Noa Cohen, Edith Lupu, Adi Kedmi, Orian Zilberman, Avital Jayson, Arik Monash, Eyal Dor, Eran Diamant, Michael Goldvaser, Inbar Cohen-Gihon, Ofir Israeli, Shirley Lazar, Ohad Shifman, Adi Beth-Din, Anat Zvi, Ziv Oren, Arik Makovitzki, Elad Lerer, Avishai Mimran, Einat Toister, Ran Zichel, Yaakov Adar, Eyal Epstein
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
VSV
virus vaccine
bioprocess
production
fixed-bed bioreactor
genetic stability
Online Access:https://www.frontiersin.org/articles/10.3389/fbioe.2024.1333548/full

Internet

https://www.frontiersin.org/articles/10.3389/fbioe.2024.1333548/full

Similar Items